Company Info
Year Established2017
Contacts
Biao He, PhDCEO
Samuel Wu, MD, PhD
CBO
Gary Titus
CFO
Marinka Tellier, PhD
Chief Regulatory Officer
Hank Radziewicz, MD MSCR
CMO
Company Description
Cyanvac is developing vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector. ﾷ